drugset / Trial / NCT04691622
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.
Timeline
- Start
- 2022-03-17
- Primary completion
- 2028-08-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Norovirus -specific T-cell (NST) therapy | Cell therapy | 1e+07 cells | — |
| Subject | Norovirus -specific T-cell (NST) therapy | Cell therapy | 2e+07 cells | — |
| Subject | Norovirus -specific T-cell (NST) therapy | Cell therapy | 4e+07 cells | — |